SCD
SCD
SCD
Home   >   Medical Journal Articles   >   Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center.

Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center. - April 1, 2016

Obih C, Wahbeh G, Lee D, Braly K, Giefer M, Shaffer ML, Nielson H, Suskind DL. "Specific carbohydrate diet for pediatric inflammatory bowel disease in clinical practice within an academic IBD center." Nutrition (Burbank, Los Angeles County, Calif.) 32.4 (2016): 418-25.
https://www.ncbi.nlm.nih.gov/pubmed/26655069

 

Abstract

OBJECTIVE:

Despite dietary factors being implicated in the pathogenesis of inflammatory bowel disease (IBD), nutritional therapy, outside of exclusive enteral nutrition (EEN), has not had a defined role within the treatment paradigm of pediatric IBD within IBD centers. Based on emerging data, Seattle Children's Hospital IBD Center has developed an integrated dietary program incorporating the specific carbohydrate diet (SCD) into its treatment paradigm. This treatment paradigm uses the SCD as primary therapy as well as adjunctive therapy for the treatment of IBD. The aim of this study was to evaluate the potential effects of the SCD on clinical outcomes and laboratory studies of pediatric patients with Crohn's disease (CD) and ulcerative colitis (UC).

METHODS:

In this retrospective study, we reviewed the medical records of patients with IBD on SCD.

RESULTS:

We analyzed 26 children on the SCD: 20 with CD and 6 with UC. Duration of the dietary therapy ranged from 3 to 48 mo. In patients with active CD (Pediatric Crohn's Disease activity index [PCDAI] >10), PCDAI dropped from 32.8 ± 13.2 at baseline to 20.8 ± 16.6 by 4 ± 2 wk, and to 8.8 ± 8.5 by 6 mo. The mean Pediatric Ulcerative Colitis Activity Index for patients with active UC decreased from a baseline of 28.3 ± 10.3 to 20.0 ± 17.3 at 4 ± 2 wk, to 18.3 ± 31.7 at 6 mo.

CONCLUSION:

This retrospective review provides evidence that the SCD can be integrated into a tertiary care center and may improve clinical and laboratory parameters for pediatric patients with nonstructuring, nonpenetrating CD as well as UC. Further prospective studies are needed to fully assess the safety and efficacy of the SCD in pediatric patients with IBD.